Linked Life Data

16971265

Source:http://linkedlifedata.com/resource/pubmed/id/16971265

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-9-14
pubmed:abstractText
The number of patients who have hepatocellular carcinoma (HCC) is expected to more than double over the next 1 to 2 decades. Patients who have cirrhosis, regardless of cause, are at the highest risk for developing HCC. This article discusses surveillance of these patients for HCC by alpha-fetoprotein and ultrasound, evaluation using imaging, classification of HCC using the Barcelona staging classification, and treatment. Resection, transplantation, and percutaneous ablation are considered curative interventions and are applied to about 30% of all patients who have HCC. Currently, there is no standard therapy for advanced HCC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1089-3261
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
339-51, ix
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Hepatocellular carcinoma.
pubmed:affiliation
Division of Gastroenterology, Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA. jmarrero@umich.edu
pubmed:publicationType
Journal Article, Review